Source: CureToday articles
The FDA’s ODAC has voted against the risk/benefit profile of two targeted therapies for the treatment of bladder and prostate cancer, respectively.
Recent Content
- Ambulatory Pharmacy in Action: House Calls and Harm Reduction Clinics Expand the Reach of Care
- Detailing the Potential Benefit of Intratumoral Therapies in Lung Cancer
- Reimagining Pain Management: Pharmacists Urged to “Deconstruct the Cupcake”
- Specialty Pharmacist Integration in Neurology Clinics: A Model for Enhanced Patient Care
- Targeted Chemo Improves Survival in Early-Stage Lung Cancer
- Utilizing AI in Prostate Cancer Care and Management
- KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety
- Rilonacept in Recurrent Pericarditis: Mechanism of Action, Patient Management, and Clinical Considerations
- Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation
- Op-Ed: Expand Patient Choice to Lower Medication Costs